This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?
by Zacks Equity Research
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CI's Unit Unveils Offering to Expand Access to GLP-1 Medications
by Zacks Equity Research
Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.
Is it a Good Idea to Invest in Immunocore Stock Right Now?
by Zacks Equity Research
IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.
EHC Opens Rehabilitation Unit in Fort Myers, Boosts Florida Footprint
by Zacks Equity Research
Encompass Health inaugurates the Rehabilitation Hospital of Fort Myers in partnership with Lee Health to provide high-quality rehabilitation services across Florida.
Factors That Make Centene Stock a Lucrative Pick Right Now
by Zacks Equity Research
CNC remains well-poised for growth on improved premiums, a well-performing Commercial Marketplace business, strategic divestitures and sound cash reserves.
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock
by Zacks Equity Research
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 20% and 8.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 29.41% and 1.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
by Zacks Equity Research
CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year.
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for November 8th
by Zacks Equity Research
CRMD, FFIC and SPPJY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2024.
New Strong Buy Stocks for November 8th
by Zacks Equity Research
SPPJY, FFIC, CRMD, NTGR and AACAY have been added to the Zacks Rank #1 (Strong Buy) List on November 8, 2024.
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 50% and 4.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Atossa Genetics Inc. (ATOS) and CorMedix (CRMD) have performed compared to their sector so far this year.
Here's Why CorMedix (CRMD) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know
by Zacks Equity Research
Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think CorMedix (CRMD) Could Surge 117.77%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 117.8% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 142.25%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 3.85% and 7.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 135.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.